Evidence map›Paper›PMID 32414847›Full record

ArticleHaematologica2021

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients.

Bruno Cassinat, Emmanuelle Verger, Nabih Maslah, Nicolas Gauthier, William Vainchenker, Stéphane Giraudier, Jean-Jacques Kiladjian

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Atypical CML: diagnosis and treatment.Hematology. American Society of Hematology. Education Program · 2023
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Bruno CassinatAP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
Emmanuelle VergerAP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
Nabih MaslahAP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
Nicolas GauthierCentre d’Investigations Cliniques, Hôpital Saint-Louis, Paris
William VainchenkerLaboratoire d’Excellence GR-Ex, Université de Paris, Paris
Stéphane GiraudierAP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
Jean-Jacques KiladjianUniversité de Paris, U1131 INSERM, Paris
Hôpital Saint-Louis · FRAssistance Publique – Hôpitaux de Paris · FRLaboratory of Excellence GR-Ex · FRParis Cardiovascular Research Center · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone Marrow NeoplasmsMyeloproliferative DisordersCyclin D2Drug Resistance, NeoplasmFusion Proteins, bcr-ablHumansMutationCCND2 protein, humanCyclin D2Fusion Proteins, bcr-abl

Identifiers

PMID32414847
PMCPMC7927990
OpenAlexW3024420270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.